AAAna Abreu

Ana Abreu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Abreu has a total of 825 co-authors. Here are the top co-authors by number of shared publications:

  • Helena Santa-Clara

    1, Exercise and Health Laboratory, CIPER, Faculty of Human Kinetics, University of Lisbon, 1495-751 Cruz Quebrada, Portugal 2, ICPOL – Police Science Research Centre, Higher Institute of Police Sciences and Internal Security, 1300-663 Lisbon, Portugal 3, Insight, Research Unit in Human Movement Analysis, Instituto Piaget, 2805-059 Almada, Portugal

    7 shared publications
  • Rui Ferreira

    Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar Lisboa Central, CHLC, Lisboa, Portugal

    6 shared publications
  • Dirk De Bacquer

    Department of Public Health and Primary Care, Ghent University , Ghent

    5 shared publications
  • Lars Rydén

    Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

    5 shared publications
  • Andreia Mamede

    4 shared publications
  • Catriona Jennings

    Honorary Professor and Director of Nursing and Interdisciplinary Relations, National Institute for Prevention and Cardiovascular Health, University of Galway

    4 shared publications

Latest Publications

  • European Society of Cardiology guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey

    by David A Wood, Catriona S Jennings, Kornelia Kotseva, Agnieszka Adamska, Iris Erlund, Sandra Ganly, Per-Henrik Groop, Susan Hennessy, Maarten J G Leening, Linda Mellbin, et al.

    Background and Aims: We investigated whether patients with coronary heart disease (CHD) in Europe are achieving the standards set by prevention and rehabilitation guidelines. Variability in achieved standards was also studied: (i) between countries, (ii) between geographical risk regions, and (iii) according to attendance at cardiac rehabilitation (CR). Methods: EUROASPIRE VI is an observational study conducted between September 2024 and February 2026 in 160 hospitals across 27 countries. Geographical risk regions were defined as high, moderate, or low based on World Health Organization cardiovascular mortality data. Results were standardized by age and sex. Results: Among 8590 patients with CHD (23.7% female), 17.1% were current smokers, 32.0% were obese, and 33.5% reported low physical activity. 59.8% were above blood pressure target (systolic ≥130 and/or diastolic ≥80 mmHg), 82.7% were above LDL-cholesterol target (≥1.4 mmol/L), 32.8% had known diabetes of whom 42.2% had HbA1c ≥7%, and 30.6% had chronic kidney disease. Prevalences of these risk factors were all highest in countries from high-risk regions. 29.1% of patients attended at least one CR session, with country variability ranging from 0% to 79% and differing by risk region (55.9% low risk, 29.7% moderate risk and 10.2% high risk; P < .001). Attendance at CR programmes was associated with significantly better lifestyles, risk factor control, and use of cardioprotective drugs. Conclusions: Most European patients are not achieving targets set by prevention guidelines. Despite better outcomes for those attending CR, there is marked variability in CR attendance and evidence of inverse care, with lowest attendance in highest risk regions. These results provide a baseline to inform the challenges for future implementation of the first European Society of Cardiology guideline on CR.


  • Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors

    by Amina Rakisheva, Giandomenico Disabato, Ana Abreu, Andrea Attanasio, Johann Bauersachs, Michael Becker, Bert Callewaert, Camil Castelo-Branco, Serenella Castelvecchio, Julie De Backer, et al.

    Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may be influenced by sex-specific hormones and pathologies that need to be addressed to improve prevention and treatment. This expert consensus statement aims to provide a comprehensive roadmap for HF prevention and management across specific conditions affecting women during their life-course. Each section focuses on the impact of a specific female condition on CVD and how to prevent and manage HF in specific settings: 1. Pregnancy with a specific focus on how to deal with hypertensive disorders in the acute and chronic setting and how to prevent and treat Peripartum Cardiomyopathy (PPCM); 2. Gynecological conditions predisposing to HF, such as Polycystic Ovary Syndrome (PCOS), endometriosis, and the menopausal transition. Emphasis is placed on chronic inflammation, metabolic dysfunction, and the “window of opportunity” for Menopausal Hormone Therapy (MHT); 3. Cardio-Oncology: mitigating Cancer Therapy-Related Cardiac Dysfunction (CTRCD) in breast and gynecological cancers, focusing on female-specific cardiotoxicity profiles, the importance of subclinical detection of cardiac dysfunction and the implementation of cardioprotective strategies (ACE-inhibitors, Beta-blockers, SGLT2 inhibitors) during cardiotoxic treatments. Lifestyle interventions such as the DASH diet and exercise-based rehabilitation are highlighted as essential for maintaining cardiac reserve.


  • Prevention of heart failure

    by Massimo Piepoli, Giuseppe Rosano, Ana Abreu, Marianna Adamo, Andrea Attanasio, Ovidiu Chioncel, Alain Cohen-Solal, Gerasimos Filippatos, Eva Gerdts, Andreas Gevaert, et al.

    Heart failure (HF) remains a major cause of morbidity, mortality and costs for the healthcare systems worldwide, despite advances in diagnostic and therapeutic strategies. The enhancement of preventive measures is now a priority, but effective prevention requires a multidisciplinary strategy addressing a broad spectrum of comorbidities and risk factors. It must also consider the changes in the prevailing phenotype of the patients with HF with a lower impact of coronary artery disease and the increasing role of renal and metabolic conditions leading mostly to HF with preserved ejection fraction. Prevention of HF must take into consideration arterial hypertension, chronic kidney disease, diabetes mellitus, sedentary lifestyle, obesity, dyslipidemia, female-specific risk factors, as well as adverse effects of chemotherapy and radiotherapy. Other key factors include infections and the protective role of vaccination, and environmental and socio-economic determinants of health. In 2022, a position paper of the Heart Failure Association and the European Association of Preventive Cardiology of the ESC was published as a complete overview on this topic and as a compendium to the 2021 ESC Guidelines on HF. However, since then, significant evidence has emerged regarding the potential to prevent HF, particularly in the context of metabolic disorders, diabetes and kidney diseases. This scientific statement aims to provide an updated perspective, highlighting the importance of a holistic and tailored approach to managing the multifaceted contributors to this syndrome.


  • Ventricular free-wall rupture, ventricular pseudoaneurysm, and papillary muscle rupture complicating acute myocardial infarction

    by Roberto Lorusso, Matteo Matteucci, Daniele Ronco, Giulio Massimi, Susanna Price, Martin Czerny, Rodrigo Estévez-Loureiro, Matthias Siepe, Gianluca Pontone, Christian Hassager, et al.

    The prevalence of mechanical complications following acute myocardial infarction has steadily declined in recent years owing to advances in prompt coronary revascularization, and they now occur in <1% of acute myocardial infarction cases. Nevertheless, significant haemodynamic impairment may already be present at hospital admission, requiring immediate diagnostic evaluation and urgent intervention. Until recently, surgical repair was the only treatment option, with non-negligible in-hospital mortality rates, particularly among patients with acute cardio-circulatory failure. Advances in transcatheter percutaneous procedures have now introduced alternative treatment strategies, especially for high-risk or inoperable patients. Recurrence of post-acute myocardial infarction mechanical complications, even shortly after the repair of the underlying lesion, has a critical impact on patient outcome and underscores the need for careful monitoring during hospitalization as well as after discharge. The role of concomitant coronary revascularization remains controversial, with variable effects on both early and late outcomes, and warrants further investigation. Temporary mechanical circulatory support has shown encouraging results, either for pre-procedural haemodynamic stabilization (‘bridge-to-procedure’) or for prophylactic, extended peri-procedural support to facilitate myocardial recovery (‘bridge-to-recovery’). Optimal management should be guided by a multidisciplinary Heart Team approach (including Shock Team involvement where appropriate) with integration of palliative care into the decision-making process.


  • Ventricular free-wall rupture, ventricular pseudoaneurysm, and papillary muscle rupture complicating acute myocardial infarction

    by Roberto Lorusso, Matteo Matteucci, Daniele Ronco, Giulio Massimi, Susanna Price, Martin Czerny, Rodrigo Estévez-Loureiro, Matthias Siepe, Gianluca Pontone, Christian Hassager, et al.

    The prevalence of mechanical complications following acute myocardial infarction has steadily declined in recent years owing to advances in prompt coronary revascularization, and they now occur in <1% of acute myocardial infarction cases. Nevertheless, significant haemodynamic impairment may already be present at hospital admission, requiring immediate diagnostic evaluation and urgent intervention. Until recently, surgical repair was the only treatment option, with non-negligible in-hospital mortality rates, particularly among patients with acute cardio-circulatory failure. Advances in transcatheter percutaneous procedures have now introduced alternative treatment strategies, especially for high-risk or inoperable patients. Recurrence of post-acute myocardial infarction mechanical complications, even shortly after the repair of the underlying lesion, has a critical impact on patient outcome and underscores the need for careful monitoring during hospitalization as well as after discharge. The role of concomitant coronary revascularization remains controversial, with variable effects on both early and late outcomes, and warrants further investigation. Temporary mechanical circulatory support has shown encouraging results, either for pre-procedural haemodynamic stabilization (‘bridge-to-procedure’) or for prophylactic, extended peri-procedural support to facilitate myocardial recovery (‘bridge-to-recovery’). Optimal management should be guided by a multidisciplinary Heart Team approach (including Shock Team involvement where appropriate) with integration of palliative care into the decision-making process.


  • Environmental risk factors and cardiovascular health

    by Massimo Piepoli, Franz Weidinger, Victor Aboyans, Ana Abreu, Zorana Jovanovic Andersen, Jordi Baneras, Michele Carugno, Elisabetta Cerbai, Serenella Castelvecchio, Andreas Daiber, et al.

    Environmental risk factors—air pollution, noise, heat, chemical contamination, and light pollution—are increasingly recognized as key contributors to cardiovascular disease but remain underrepresented in clinical guidelines and public health strategies. This comprehensive review, developed under the auspices of the European Society of Cardiology (ESC), synthesizes current evidence on the cardiovascular consequences of environmental exposures. Building on prior ESC recommendations on air pollution, the consensus statement extends the focus to include climate change, urban heat islands, chemical pollutants, noise, and light pollution, highlighting their shared pathophysiological mechanisms: oxidative stress, inflammation, endothelial dysfunction, and circadian disruption. Epidemiological and experimental studies confirm that these exposures exacerbate the incidence of coronary artery disease, stroke, heart failure, arrhythmias, and hypertension—even at levels below existing regulatory thresholds. It is proposed the exposome framework as a conceptual tool to understand the cumulative lifetime impact of environmental hazards on cardiovascular health. Special attention is given to vulnerable populations, including children, the elderly, socioeconomically disadvantaged groups, and patients with pre-existing cardiovascular disease. The document outlines urgent research needs, such as the need for high-resolution exposure data, exploration of gene–environment interactions and molecular pathways, and the development of real-world and mechanistic studies assessing interventions. Mitigation strategies are discussed across individual, clinical, and policy levels, with a call for heart-healthy urban design, stricter emissions legislation, and equitable access to clean environments. Cardiologists are uniquely positioned to advocate for environmental cardiovascular health, bridging the gap between science, clinical care, and policy. This statement aims to accelerate that translation by raising awareness and promoting action across disciplines.


  • Open Access

    Ultra-processed foods, lifestyle management, and cardiovascular diseases

    by Luigina Guasti, Marialaura Bonaccio, Ana Abreu, Riccardo Asteggiano, Maira Bes-Rastrollo, Ruxandra Christodorescu, Giovanni de Gaetano, Marc Ferrini, Pedro Marques-Vidal, Atul Pathak, et al.

    Ultra-processed foods (UPFs) have increasingly displaced traditional diets globally and have become a significant public health concern, particularly in relation to cardiovascular (CV) diseases. UPFs are defined as food products primarily composed of cheap industrial ingredients, additives, and neo-formed compounds, often with little to no nutritional value. These foods are highly processed and contain additives that can have harmful effects on health. While traditional dietary guidelines have long emphasized the importance of limiting animal-derived fats and promoting the intake of fruits, vegetables, and unsaturated fats, recent evidence suggests that the extent and nature of food processing are also key factors in the relationship between diet and health. Studies over the past decade have highlighted that the consumption of UPFs is associated with increased CV risk, often independent of the overall diet quality. Despite growing evidence linking UPF consumption to major CV risk factors (e.g. hypertension, dyslipidaemia, obesity) and adverse CV outcomes, the role of food processing in CV health remains underrecognized in cardiology. Current dietary counselling in clinical practice tends to overlook the potential adverse impact of UPFs, with patients not receiving comprehensive nutritional guidance. This European Society of Cardiology (ESC) clinical consensus statement, developed by a multidisciplinary group of European experts, is conceived to increase awareness among clinicians about the CV risks associated with UPFs. Starting from a comprehensive review of current evidence, it provides practical, actionable advice to help the general cardiologists incorporate UPF-related assessment and counselling into their routine care. The statement also proposes a stepwise framework focused on CV prevention, including tools designed to enhance patient communication and engagement. Moreover, it discusses these clinical advices within wider strategic and policy frameworks, therefore supporting a more integrated, food-centred approach to improve CV health.


  • Climate change and cardiovascular risk factors management: emerging challenges and strategies for prevention and adaptation

    by Maria Marketou, Norma Caples, Mark Abela, Paul Dendale, Özden Gökdemir, Oleksii Korzh, Donata Kurpas, Ming-Nan Lin, Anna Vittoria Mattioli, Trine Moholdt, et al.

    Climate change represents an escalating global health crisis that profoundly influences the risk factors for cardiovascular disease (CVD). Human-driven alterations in climate—including rising ambient temperatures, more frequent and severe heatwaves, air pollution, and extreme weather events—directly and indirectly exacerbate hypertension, diabetes, hyperlipidaemia, and physical inactivity. Exposure to high temperatures and pollution promotes vascular dysfunction, inflammation, and oxidative stress, leading to worsened blood pressure control, dysglycaemia, and disrupted lipid metabolism. Extreme weather events, floods, and wildfires trigger acute spikes in cardiovascular events through dehydration, myocardial ischaemia, and arrhythmias, while also disrupting healthcare delivery and medication adherence. Moreover, climate-driven changes in food systems and nutritional quality exacerbate unhealthy dietary behaviours, further amplifying cardiometabolic risk. Vulnerable populations—including older adults, racial and ethnic minorities, and those of lower socioeconomic status—bear a disproportionate burden of these effects. Mitigating the cardiovascular consequences of climate change requires integrated approaches that incorporate climate-sensitive risk stratification, targeted education of patients and clinicians, and adaptive health system responses. Primary care physicians play a central role in delivering anticipatory guidance and equitable care to at-risk individuals. This review synthesizes evidence linking climate change with CVD risk profiles. It outlines clinical and public health strategies to strengthen climate resilience in cardiovascular medicine.


  • Cuffless Blood Pressure Monitoring Devices: Technical Foundations and Clinical Implications

    by Gianfranco Parati, Juan Eugenio Ochoa, Ana Abreu, Sofie Brouwers, Rosa Maria Bruno, Enrico G Caiani, Ruben Casado-Arroyo, Matthijs Cluitmans, Constantinos H Davos, Raffaele De Lucia, et al.

    Cuffless blood pressure (BP) monitoring devices represent a promising innovation in hypertension management. This scientific statement provides a comprehensive update on these emerging technologies, their specific validation requirements, their potential clinical applications, and their present and future challenges. These devices generate considerable interest by enabling non-invasive BP measurement without arterial occlusion, thereby eliminating the discomfort associated with traditional cuff-based monitoring, particularly during sleep. The technologies on which these devices are based comprise a heterogeneous group, primarily utilizing pulse wave propagation time or waveform analysis through contact or non-contact sensors. They can be categorized as continuous or intermittent, automated or manual, calibration-free or requiring cuff/demographic calibration, and wearable or stationary. This technological diversity necessitates validation protocols distinct from those used for conventional cuff-based monitors, with specific requirements for each device category. Potential clinical applications include widespread out-of-office BP monitoring, unbiased assessment of circadian BP patterns and BP variability, improved detection of nocturnal hypertension, enhanced treatment adherence and long-term BP control, and continuous monitoring in hospital settings. Additionally, their lower cost compared with conventional technologies could enhance the early detection of hypertension in resource-limited settings. However, due to insufficient accuracy validation, this scientific statement does not recommend their use in clinical decisions in spite of their potential interest, in line with international guidelines not recommending their use in hypertension management. Key challenges ahead include developing standardized validation protocols, establishing normative BP data, managing the resulting burden on clinicians in handling huge volumes of data, exploring additional haemodynamic parameters, and advancing sensor technology, mathematical models, and algorithms.


  • Open Access

    Anxiety and depression and secondary prevention of coronary heart disease in 14 countries across six WHO regions: the INTERASPIRE study

    by Chantal F Ski, Catriona S Jennings, Dirk De Bacquer, Kornelia Kotseva, John William McEvoy, Guy De Backer, Iris Erlund, Sandra Ganly, Terhi Vihervaara, Gregory Yoke Hong Lip, et al.

    Aims: Anxiety and depression are associated with poor outcomes in patients with coronary heart disease (CHD), however their association with achieving recommended cardiovascular prevention standards is unclear. We examined this association across all World Health Organization (WHO) regions. Methods and results: Cross-sectional analysis of the INTERASPIRE study of adults hospitalized in the preceding 6–24 months with incident or recurrent CHD who underwent a standardized interview and examination (2020–2023) across 14 countries. The main outcome was the INTERASPIRE-Guideline Target Score (GTS); a 10-point assessment of achieving secondary prevention lifestyle, risk factor, and therapeutic targets. A total of 4546 patients (21.1% women) with a mean (SD) age of 60.0 (10.3) were interviewed. Prevalence’s of anxiety and/or depression were greater in women than men, and prevalence of CHD lifestyle and behavioral risk factors increased alongside severity of anxiety and depression symptoms. Compared to those without symptoms, adjusted odds ratios for achieving a suboptimal INTERASPIRE-GTS were: 1.52 (95% CI 1.13–2.04, P = 0.006) for symptoms of depression; 1.57 (95% CI 1.09–2.26, P = 0.015) for “possible” comorbid anxiety and depression; and 2.09 (95% CI 1.22–3.57, P = 0.007) for those with “probable” comorbid anxiety and depression. Conclusion: Increasing severity of depression and anxiety symptoms are associated with reduced potential for achieving guideline standards for CHD secondary prevention. Secondary prevention programs should integrate risk-stratified management of individuals with symptoms of anxiety and/or depression to improve CHD guideline targets. Lay summary: We examined if patients with symptoms of anxiety and/or depression were more or less likely to achieve guideline standards for secondary prevention of coronary heart disease (CHD).Increasing severity of symptoms of anxiety and depression was associated with reduced potential for achieving guideline standards for secondary prevention of CHD.A higher proportion of women with CHD experience more severe levels of anxiety and depression on their own, and combined as a comorbidity.Patients with CHD should be treated holistically, acknowledging the heart and mind connection.